A Gq Biased Small Molecule Active at the TSH Receptor

Rauf Latif, Syed A. Morshed, Risheng Ma, Bengu Tokat, Mihaly Mezei and Terry F. Davies

G protein coupled receptors (GPCRs) can lead to G protein and non-G protein initiated signals. By virtue of its structural property, the TSH receptor (TSHR) has a unique ability to engage different G proteins making it highly amenable to selective signaling. In this study, we describe the identification and characterization of a novel small molecule agonist to the TSHR which induces primary engagement with Gαq/11. To identify allosteric modulators inducing selective signaling of the TSHR we used a transcriptional-based luciferase assay system with CHO-TSHR cells stably expressing response elements (CRE, NFAT, SRF, or SRE) that were capable of measuring signals emanating from the coupling of Gαs, Gαq/11, Gβγ, and Gα12/13, respectively. Using this system, TSH activated Gαs, Gαq/11, and Gα12/13 but not Gβγ. On screening a library of 50K molecules at 0.1, 1.0 and 10 μM, we identified a novel Gq/11 agonist (named MSq1) which activated Gq/11 mediated NFAT-luciferase >4 fold above baseline and had an EC50 = 8.3 x 10−9 M with only minor induction of Gαs and cAMP. Furthermore, MSq1 is chemically and structurally distinct from any of the previously reported TSHR agonist molecules. Docking studies using a TSHR transmembrane domain (TMD) model indicated that MSq1 had contact points on helices H1, H2, H3, and H7 in the hydrophobic pocket of the TMD and also with the extracellular loops. On co-treatment with TSH, MSq1 suppressed TSH-induced proliferation of thyrocytes in a dose-dependent manner but lacked the intrinsic ability to influence basal thyrocyte proliferation. This unexpected inhibitory property of MSq1 could be blocked in the presence of a PKC inhibitor resulting in derepressing TSH induced protein kinase A (PKA) signals and resulting in the induction of proliferation. Thus, the inhibitory effect of Msq1 on proliferation resided in its capacity to overtly activate protein kinase C (PKC) which in turn suppressed the proliferative signal induced by activation of the predominant cAMP-PKA pathway of the TSHR. Treatment of rat thyroid cells (FRTL5) with MSq1 did not show any upregulation of gene expression of the key thyroid specific markers such as thyroglobulin (Tg), thyroid peroxidase (Tpo), sodium iodide symporter (Nis), and the TSH receptor (Tshr) further suggesting lack of involvement of MSq1 and
**INTRODUCTION**

Traditionally GPCR drug development has focused on conventional agonists and antagonists that are known to act as “on-off” switches. However, there is growing appreciation that GPCRs can mediate their physiologically relevant effects through selective signaling due to subtle structural changes and engagement of G protein and non-G protein effectors. Selective signaling can be driven by endogenous ligands, synthetic peptides or small molecules, which bind to the orthosteric or allosteric site(s) and in turn bias the downstream signal. The TSHR which is made up of a large glycosylated ectodomain and seven transmembrane helices which are connected by extracellular and intracellular loops (1) is structurally poised as a candidate for allosteric modulation with its ability to engage all four classes of G proteins (2). Studies using both modeling and mutational analysis of the TSHR have indicated the structural determinants of the G protein coupling to the receptor (3, 4). However, it is not yet fully clear as to what preferential order these different G proteins are engaged by the TSHR during activation nor the exact intra- and intermolecular interactions leading to coupling of the different G proteins by TSH or TSHR antibodies. However, crystallization of the partial ectodomain with stimulating and blocking autoantibodies (5–7) together with studies of the molecular rearrangement of the TSHR ectodomain and hinge regions has given some recent insight into the possible mechanism(s) of this activation (8, 9).

Small molecules can bind to the allosteric sites on the TSHR TMD and ectodomain (10, 11) and are excellent tools to gain insight into the potential for TSHR selective signaling. Their unique ability to readily permeate the cell membrane and interact with specific residues within the transmembrane helices can induce subtle conformational changes (12–14). In recent years there has been rapid development of small molecules, both agonists (15–17) and antagonists (16, 18–20) against the TSHR as part of a search for novel therapeutic agents. These various small molecule ligands induce the Goq pathway of the TSHR and the possibility of selective Goq/11 activation by a small molecule has not been explored. However, studies have indicated that such selectivity in signaling can be established in GPCRs and not only by different receptor subtypes (21, 22) but also via pathway bias suggesting ligand selectivity can be a potential source of a defined pharmacology for small molecules (23, 24).

In this report, we describe the identification and in vitro characterization of a novel small molecule that activates the TSHR by preferentially initiating Goq/11 signaling and then examined its biological consequences on thyrocyte proliferation and gene expression.

**MATERIALS AND METHODS**

**Establishing Double Transfected CHO-TSHR Cell Lines**

In order to identify the signaling through the four major classes of G-proteins (Goq, Gq/11 and Go12/13 and Gβγ) by the TSHR, we generated double transfected CHO-TSHR stable lines containing CRE, NFAT, SRF, or SRE response elements (RE) tagged to a modified form of luciferase reporter. These double transfected stable clones were established by selecting the cells with hygromycin (800 μg/ml) and 500 μg/ml of G418 (neomycin sulfate). Following initial screening and validation, these stable cell lines were maintained in Ham’s F-12 medium with 10% fetal bovine serum (FBS), 100 units of penicillin and streptomycin with 200 μg/ml of hygromycin and G418 to maintain the selection pressure in these co-transfected cells. Using the individually co-transfected stable lines containing the respective response elements, we screened a 50K chemical library at 0.1, 1 and 10 μM against CRE, NFAT, SRF, and SRE cells in a 384 well format following the protocol described previously (17).

**Treatment and Lysate Preparation**

For downstream signaling studies, low passage number of FRTL5 cells were cultured in 60 mm dishes using Hams F12 medium with 5% calf serum to which 1X 6H (6 hormone mixture) was added as previously described (25). Once the cells reached 60–80% confluence, cells were washed twice with plain medium and then cultured further in Ham F12 medium containing only 5H hormone (-TSH) for 72 hrs. Following this the cells were washed twice with plain F12 medium and incubated for another 48 h in Ham’s F12 medium containing 0.3% BSA (basal medium). These cells were then either stimulated with increasing dose of MSq1, TSH or MS438 or combination of TSH plus MSq1 or TSH+MSq1+ PKC inhibitor at 2 μM (G06883) as per the experimental details described under figure legends for 48 h at 37C. Lysates from these treated cells were prepared using 1X Novagen phosphosafe extraction buffer as per the manufacturer’s instructions and total protein in the lysate estimated by Bradford.

**References**

1. Latif et al. Gq Agonist Against the TSHR

**Abbreviations:** TSHR, Thyroid stimulating receptor; GPCR, G protein coupled receptors; GD, Graves’ disease; TMD, transmembrane domain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
blocking membranes with 2% BSA for 2 h at RT or subjected to protein quantification using simple western system by the WES machine for immunoblotting and detection (ProteinSimple, Santa Clara, CA, USA).

**Immunoblotting and Detection**

In the present study, we quantitated the absolute response to PKC and PKA in the lysate prepared from the treated cells as described above. pPKC was detected by classical immunoblotting procedure described earlier (27) using commercially obtained primary antibodies to pPKC βII ser660, Anti-rabbit HRP (1:20,000) in 1X tris-borate saline with tween 20 0.5% (TBST) was used as detection antibody and the immunoblots developed with ECL. Quantitation of pPKA was carried out using the protein simple WES system after titrating the primary and secondary antibodies against different concentrations of the samples. Briefly, the WES protocol is as described here, first, a 0.2 µg of lysate was mixed with master mix to achieve a final concentration of 1X sample buffer in the presence of fluorescent molecular weight marker and 40 mM dithiothreitol, the samples were denatured at 95°C for 5 min. Target proteins were immunoprobed with primary antibody pPKA (thr197) followed by HRP-conjugated secondary antibodies. All antibodies were diluted using an antibody diluent at a 1:100 or 1:200. Detection of ERK 44-kDa protein in the lysate using anti ERK served as a positive run control in addition to the biotinylated ladder for size estimation. β-actin was used as the loading control. Digital images of the signal were analyzed with Compass software (ProteinSimple), and the quantified data of the detected proteins with the correct molecular weight is reported as signal/noise ratio derived from average signal intensity exposures.

**Proliferation Measured by Alamar Blue**

Proliferation of FRTL5 cells was measured using Alamar Blue, which monitors the reducing environment of the living cell. The active ingredient is resazurin, which is a stable, nontoxic and permeable compound, which accepts electrons and changes from the oxidized, non-fluorescent, blue state to the reduced, fluorescent, pink state. These studies were carried out on FRTL5 grown on black clear bottom 96 well plates. Cells in the log phase were harvested by trypsin and seeded as 30 × 10^3 cells/well and allowed to adhere to the bottom of plate in complete HamF12 medium by incubating the cells with 6H overnight at 37°C. Following a 24 to 36 hrs incubation, the cells were culturally prepared by removing TSH for 3 days prior to induction of proliferation as described earlier. The cells were then exposed to MSq1, TSH or combination of both with and without the PKC inhibitor as per the experiment described under figure legends. For determining the effect of a small molecule or TSH on cell growth, we had stimulated vs. unstimulated cells. Following 48 h of treatment, Alamar Blue was aseptically added to each well in an amount equal to 10% of the volume in the wells. Cells with Alamar Blue were further incubated at 37°C for another 5 h prior to reading the plates. Proliferation was assessed by measuring fluorescence intensity of the reduced dye at 540/580 nm. Wells with media plus dye only was used as the background control. Log change between untreated over that of treated groups was deduced from the fluorescent intensities obtained after background subtraction.

**Docking and Contact sites**

Docking of the lead MSq1 molecules was performed on a homology model of the TSHR-TMD based on rhodopsin (PDB:1F88). This template was chosen because of the low RMSD values between the backbone of the TM helices of the TSHR model and that of the rhodopsin x-ray crystal structure (14) and fits the experimental parameters that we have previously described (15). The initial homology model of rhodopsin TMD was obtained from the Uniprot server (http://www.uniprot.org). The conformations of the extracellular loops were constructed with a Monte Carlo method (16). The 3D geometries of the docked ligands were generated with MarvinSketch (http://www.chemaxon.com). Multiple docking was carried out using the programs Glide, Au todock-4 and Autodesk-Vina. The docking results were analyzed using Dockres and other supporting script tools (17). In particular, Dockres extracts the coordinates of the docked poses from the docking log file and identifies contacts between the ligand and target as pairs of mutually proximal atoms and hydrogen bonds (if any) as X...H-X’ where X and X’ are polar atoms (one on the ligand and the other on the target) with X...H distance within threshold and X...H-X angle is greater than 120 deg.

**IP-One Assay**

In principle PLC is the main intracellular effector enzyme of Gαq/11-coupled GPCRs. PLC hydrolyzes PIP2 into IP3 and DAG. The intracellular second messenger IP3 is rapidly degraded by phosphatases and recycled back via inositol into cell membrane PIP2. Thus, for measuring Gαq/11 activation by MSq1 in CHOTSFR cells we used the Cisbio IP-One Gq kit which is a competitive immunoassay intended to measure myo-inositol-1phosphate (IP1) accumulation in cells. The inositol phosphate accumulation assay utilizes the ability of lithium to inhibit the breakdown of inositol monophosphates and detects this accumulated IP1 by HTRF® technology. In the assay native IP1 produced by cells or unlabeled IP1 (standard curve) compete with d2-labeled IP1 (acceptor) for binding to anti-IP1-Cryptate (donor). The specific signal (i.e., energy transfer) is inversely proportional to the concentration of IP1 in the standard or sample. 50 × 10^3 CHOTSFR cells per well were seeded in 96 well black plates in complete Hams F12 medium and incubated overnight at 37°C. The adherent cells were gently washed once with warm plain medium with low serum (2%) and the cells were treated with increasing doses of TSH (µU) or MSq1 (µM) in stimulation buffer containing 50 mM of lithium chloride. At the end of 2 h incubation the cells were lysed using the lysis buffer provided and treated with detection antibodies as per manufacture’s instructions and run along with the standards provided in the kit. The measurement of acceptor (665 nm) to donor (620 nM) emission was obtained using the microplate plate reader ClarioStar and ratio calculated and interpolated to standard curves to calculate the values of the unknown samples.
ML-1 and FT236, two follicular cancer lines, were grown in DMEM high glucose with 10% FBS, 200 mM glutamine, 1x sodium pyruvate 1X Minimum essential medium with 100 units of penicillin and streptomycin. The cells were detached from the plate non-enzymatically using 1 mM EGTA/EDTA and washed twice with 1X PBS, filtered using 75 micron filter and total cells counted. 0.5 × 10^6 cells/tube were suspended in 100 ul of FACs staining buffer (1X PBS with 0.2% sodium azide and 2% FBS) with anti TSHR mAb RSR1 mouse Mab (0.1 µg/ml) and incubated for 1 h at room temperature. Following 2x wash with FACs buffer (1X PBS with 0.02% sodium azide) and the bound TSHR receptor antibodies were detected using anti-mouse antibody Fab’ phycoerthrin (PE) labeled secondary antibody at 1:200. Unstained cells, isotype antibody or secondary antibody alone were used as controls in the assay. The results were expressed as the percentage positive cells detected in the test samples compared to the controls by the vertical gates assigned based on the controls.

Gene Expression
For gene expression analysis, total RNA was extracted using a RNeasy kit and was treated with ribonuclease-free deoxyribonuclease. Five micrograms of total RNA were reverse transcribed into cDNA using the SuperScript III system. All Q-PCRs was performed using the Step OnePlus Real-time PCR system (Applied Biosystems, Foster City, CA). The reactions were established with 10 µL of SYBR Green master mix (Applied Biosystems, Foster City, CA), 0.4 µl (2 µM) of sense/anti-sense gene-specific primers, 2 µl of cDNA and DEPC-treated water to a final volume of 20 µl. The PCR reaction mix was denatured at 95°C for 60 s before the first PCR cycle. The thermal cycle profile was used is as follows: denaturizing for 30 s at 95°C; annealing for 30 s at 57–60°C (dependent on primers); and extension for 60 s at 72°C. A total of 40 PCR cycles were used. For each target gene, the relative gene expression was normalized to that of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene. Data presented as fold change in relative gene expression are from two independent experiments in which all sample sets was analyzed in triplicate.

Statistical Analyses
All curve fitting and P value calculations (one-way ANOVA) were carried using GraphPad Prism 5 software. All assays were performed at least 2 or 3 times as indicated. In case of immunoblot one representative experiment is shown.

RESULTS
Identification of a Unique Gq Activator
In order to identify allosteric ligands that can activate different G proteins of the TSHR we first developed a series of CHO-TSHR cells that were transfected with different response elements tagged to luciferase that can specifically identify the activation of specific G proteins as indicated schematically in Figure 1A. The activation of these different response elements was validated using bovine TSH as indicated in Figure 1B. This analysis clearly indicated that TSH was capable of activating Gaq, Gq11, and Gq12/13 in a dose-dependent manner. No activation was observed of Gβγ in this system. The respective positive controls used for each of the response elements are indicated and explained in the figure legends.

Screening a 50K library at 0.1, 1 and 10 µM against this panel of stable CHO TSHR luciferase cells allowed us to identify a small molecule, which preferentially activated CHO-TSHR-NFAT luciferase cells. Further examination of this Gq activator (named MSq1) against CHOTSHR-NFAT, which couples Gaq/11, and CHO-TSHR-CRE, which measures activation via Gαs, in a dose-dependent manner (Figure 2A) showed MSq1 to be a potent activator of Gq with an EC50 = 8.3 × 10^-8 M after normalizing the data to max TSH (100 μU/ml). MSq1 had only minor activation toward Gs thus making this molecule a preferential Gq activator. Structurally this molecule differed from any of the known agonist or antagonist small molecules (Figure 2B). Control studies with MSq1 measuring its influence on activation in normal CHO cells (without a TSHR) but transfected with either NFAT luciferase or CRE luciferase at 10 µM showed no activation of luciferase (Figure S1). We have shown that MSq1 is incapable of activating either Gαq or G12/13 using the luciferase system further confirming that this is a Gaq/11 biased novel small molecule (Figure S2).

Binding Sites of MSq1 by Docking Studies
We examined the binding sites of this Gq activator by in-silico docking using the structure of the TSHR TMD region developed by homology modeling and based on the rhodopsin crystal structure (as detailed in Methods). Using the top scoring docking poses generated by Autodock-4 and the criterion of ≤ 4Å, the putative contact points of MSq1 within the TSHR TMD were deduced. Like most allosteric small molecules against the TSHR, the MSq1 sites were nestled in the “hydrophobic pocket” formed by the different helices within the TSHR TMD (Figure 3A). Further analysis indicated that MSq1 made major contact points on the TSHR TMD helices H1, H2, H3, and H7 within the hydrophobic pocket and the extracellular loops including L2-3 & L4-5 (Figure 3B). When these contact residues were compared to our Gaq agonist MS438 some overlapping, and some unique residues could be observed as shown in Table 1 which lists the top-scoring Glide, Autodock-4 and Autodock-Vina poses for both MS438 and MSq1.

Downstream Signaling of the Gq Activator
Since the in-silico modeling confirmed the potential binding of MSq1 to the TSHR TMD, we examined the key downstream signals that are known to be driven by Gq activation. Activation of PLC was assayed by measuring IP1 accumulation, which showed that MSq1 and TSH were capable of significantly increasing IP1 generation (Figure 4A). Furthermore,
FIGURE 1 | Activation of the TSH receptor and G proteins. (A) Schematic representation of double transfected CHO-TSHR cells generated to study activation of the different G proteins. Shown are the 4 luciferase tagged response elements (REs) that are capable of measuring the activation of the respective second messengers used by the G proteins. (B) The bar graph panels represent the dose-responses with TSH (10 µU to 10^5 µU/ml) and the respective positive controls used with each of the double transfected stable cells. The change in activity is represented as fold change of luciferase units (LU) on the Y-axis. The gray bars marked with C+ in the x-axis are the positive controls for each of the response elements. The positive controls used were as follows: CRE - forskolin 5 uM, NFAT - ionomycin 100 µM, SRF - 20% serum + PMA 10 ng and SRE – 20% serum. The data represented here are from 3 separate experiments. Note that all the data shown here are baseline subtracted.

FIGURE 2 | (A) Potency of selected Gαq/11 agonist Msq1. Dose-response relationship of Msq1 against the NFAT and CRE response element containing cells. A 4-fold increase of NFAT luciferase was observed with Msq1 compared to a small increase in CRE luciferase showing that Msq1 is biased toward Gαq/11 signaling. (B) Molecular structure of Msq1. Chemical structure and SMILE of Msq1. The blue represents the nitrogen atoms and red corresponds to the oxygen atoms in a carbon backbone. Chemically it is 2-(4-propylphenyl)-N-(4-pyridinylmethyl)-4-quinolinecarboxamide. Name:C1(C2=C=CC=CN=C2N=C(C=C=O)(=CC=2) CO) C=1 C=C1CC1=CC=C1.
FIGURE 3 | (A) Binding of MSq1 molecule to the TSHR TMD. A homology model of the TSHR transmembrane domain, previously described (28), was used as the template for docking studies. Analysis of the Autodock results as detailed in Materials and Methods indicated that MSq1, like other small molecules, docks into a hydrophobic pocket of the TSHR TMD and in this case makes contact with residues in helices H1, H2, H3, H6, and H7 and the extracellular loops 2,3 and 4.5. (B) The TSHR TMD and its contact sites with MSq1. On extracting co-ordinates of the docked poses using Dockres, the program showed contact residues against the TSHR TMD (red semi asterisks) assessed by the criteria of $\leq 4\AA$ as indicated in this diagram. Furthermore, these contact residues in the TSHR TMD and their location within the TMD residues are indicated along with the contacts for MS438 in Table 1 for comparison.

TABLE 1 | TSHR residues on the TMD that MSq1 and MS438 contact.

| TSHR residue | Residue No # | Ballest # | MS438 rG(l-P) | rA(L-P) | rV(l-P) | MSq1 rG(l-P) | rA(L-P) | rV(L-P) |
|--------------|--------------|-----------|---------------|---------|---------|---------------|---------|---------|
| LEU          | 10           | 1.35      | 3.1           | 3.6     |         |               |         |         |
| VAL          | 14           | 1.39      | 3.2           |         |         |               |         |         |
| VAL          | 17           | 1.42      | 3.4           |         |         |               |         |         |
| LEU          | 60           | 2.57      | 3.2           | 3.2     |         |               |         |         |
| LEU          | 61           | 2.58      | 3.2           | 3.1     |         |               |         |         |
| ALA          | 64           | 2.57      | 2.9           | 2.8     | 3.5     | 2.9           | 2.8     |         |
| ASN          | 76           | L (2-3)   | 3.1           | 2.8     | 3.6     | 2.9           |         |         |
| TRP          | 81           | L (2-3)   | 3.8           |         |         | 3.1           |         |         |
| CYS          | 87           | 3.25      | 3.6           |         |         |               |         |         |
| ALA          | 90           | 3.28      | 4.0           | 3.7     |         |               |         |         |
| GLY          | 91           | 3.29      | 3.0           | 3.6     |         |               |         |         |
| THR          | 94           | 3.32      | 2.8           | 2.7     |         | 3.8           | 3.5     | 3.7     |
| VAL          | 96           | 3.33      | 3.1           | 3.6     |         | 3.1           | 3.6     |         |
| SER          | 98           | 3.36      | 3.3           | 3.4     |         | 3.4           |         |         |
| GLU          | 99           | 3.37      | 3.7           |         |         |               |         |         |
| LYS          | 158          | L (4-5)   | 3.2           |         |         |               |         |         |
| VAL          | 159          | L (4-5)   | 3.4           | 3.5     |         | 3.7           |         | 4.1     |
| ILE          | 233          | 6.51      | 3.2           | 3.4     |         |               |         |         |
| LYS          | 253          | 7.42      | 3.3           | 3.8     |         |               |         |         |
| ILE          | 254          | 7.43      | 3.3           |         |         |               |         |         |
| VAL          | 257          | 7.46      | 3.7           | 2.7     | 3.6     | 3.2           | 3.3     | 3.4     |
| LEU          | 258          | 7.47      | 3.1           | 3.2     |         | 3.5           |         |         |
| TYR          | 260          | 7.49      | 3.2           |         |         | 3.5           |         |         |
| PRO          | 261          | 7.50      | 3.1           | 3.0     | 3.6     | 3.1           |         | 3.7     |
FIGURE 4 | Gq signaling by MSq1. (A) Since Gq activation is known to result in an IP1 increase via PLC-β activation, we measured IP activation in CHO-TSHR cells with MSq1 at 0.1 and 10 µM. As indicated here MSq1 showed a significant increase (P = 0.03) in IP1 on stimulation with MSq1 which was not observed by MS438 even at 10 µM. The inset shows the dose dependent increase in IP1 with TSH. The data is plotted after background subtraction. (B) Total lysates of FRTL5 cells treated with MS438 10 µM, TSH 1,000 µU/mL and MSq1 10 uM for 24 h and the immunoblots probed for pPKC. MSq1 increased pPKC when compared to the unstimulated cells (lane 0). The 42KD β-actin was used as the loading control (*P < 0.05, **P < 0.0001).

Inhibition of TSH Induced Proliferation by Gαq/11 Activation
The physiological significance of cAMP signaling by Gαs coupling on thyrocyte growth and proliferation is well established. Since the effect of Gαq/11 on thyroid cell proliferation is not clear we examined the action of MSq1 on proliferation of thyrocytes using rat FRTL5 cells. As indicated in Figure 5A, MSq1 failed to enhance basal proliferation of thyrocytes while one of our previously published TSHR agonists (MS438) showed a dose-dependent increase in proliferation and which is known to activate the cAMP-PKA pathway like TSH. In contrast, in the presence of 10⁴ µU/ml of TSH, MSq1 inhibited the TSH induced proliferation of thyrocytes in a dose-dependent manner suggesting a suppressive action of Gq activation on the proliferative capacity of the TSH induced Gs-cAMP-PKA pathway (Figure 5B). This inhibition was only observed in TSH dependent thyrocytes and ML-1 cells derived from a human follicular carcinoma line with a high expression of TSHRs (75% expression of cell surface TSHR as established by flow cytometry) (Figure 6A) or FTC 236 cells, another follicular carcinoma line which totally lacks cell surface TSHR (Figure 6B), did not respond to MSq1 actions (Figures 6C,D). Examining gene expression for common thyroid differentiation markers such sodium iodide symporter (NIS), thyroglobulin (Tg) and the TSHR by qPCR, we did not find these markers to be upregulated in treated cells, suggesting that MSq1 activation of Gαq/11 lacked the ability to affect thyrocyte differentiation markers (Figure S3).

Release of Inhibitory Effect on Proliferation by PKC Inhibition
In order to examine the mechanism of the suppression of TSH induced thyroid cell proliferation we used a broad-spectrum
**FIGURE 5** Inhibition of thyrocyte proliferation by MSq1. (A) Rat thyrocytes seeded at 30X10^3/well of 96 well clear bottom black plate and prepared as detailed in materials and method were stimulated with increasing concentrations of MSq1 or MS438. After 48 h of stimulation in basal medium, 1/10th volume of Alamar Blue was added and incubated further at 37°C for 5 h and fluorescence emitted by the dye was measured. As seen here, MSq1 lacked the ability to stimulate proliferation of thyrocytes in comparison to MS438. (B) Similar experiments were performed under the same protocol as described above and in the presence of 10^4 µU/mL of TSH. MSq1, indicated by the light gray bars, showed significant dose-dependent inhibition of TSH-induced proliferation. However, this inhibition was specific to MSq1 since MS438, in the presence of TSH, did not inhibit proliferation but rather enhanced TSH induced proliferation at 1 and 10 µM as indicated by black bars (n = 3 *P < 0.05, **P < 0.001).

PKC inhibitor (G06983) in the presence of TSH and MSq1. As shown earlier, MSq1 treatment at 10 µM caused inhibition of TSH induced proliferation. However, in the presence of the PKC inhibitor, inhibition of proliferation by MSq1 was markedly reduced (Figure 7A). On quantitating the PKA signal using Western blotting with an anti PKA antibody, we observed that cells treated with TSH and MSq1 in the presence of the PKC inhibitor for 48 h showed significantly enhanced PKA signals compared to MSq1 plus TSH or TSH alone (Figures 7B,C). These data demonstrated that enhancement of the PKC signal by MSq1 inhibited the cAMP-PKA pathway induced by TSH activation in the thyrocytes.

**DISCUSSION**

TSH is known to induce engagement of all four classes of G protein (2) with the TSHR. However, the major pathway activated by TSH is the G_α_s pathway via PKA (29). The consequence of changing this selection is not well-understood. In particular, the role of the G_α_q/11 pathway via PKC has not been clearly clarified and it is unclear whether overt activation of this pathway has any cellular consequences. Therefore, identifying selective allosteric activators, which are biased to activating a G protein class, is one way of studying the mechanism of TSHR selective signaling and its physiological or pathophysiological effects on thyroid and extra thyroidal TSHRs. This is especially so when knock-out mouse models, which although a very valuable research tool for studying gene function, have their limitations in terms of producing an observable change and may even produce unexpected characteristics which in certain situations cannot be extrapolated to humans (30). In this report, we present data on the identification of a potent G_α_q/11 activator against the TSHR and our examination of its effects on thyrocytes.

In recent years high-throughput screening assays, combined with *in silico* structural approaches and medicinal manipulations, have resulted in the identification of a number of specific and potent agonists (16, 17, 31) and antagonists (18, 19, 32) against the TSHR which effectively activate or inhibit G_α_s initiated signals such as the cAMP-PKA pathway. Using a “tool kit” of CHO-TSHR cells harboring CRE, NFAT, SRF or SRE response elements tagged to luciferase, as shown in Figure 1A, we identified potent and specific G_α_q/11 selective small molecules. Our search found a molecule (MSq1) unlike our previously reported (17) agonist molecules which is biased toward G_α_q/11. TSH activates predominantly G_α_s (33) and G_α_q/11 when used in high (non-physiologic) concentrations (34, 35). Coupling of G_α_q/11 to the TSHR leads to activation of phospholipase C (PLC) which in turn triggers the release of intracellular calcium [Ca^{2+}], and NFAT and alternatively activates protein kinase C (PKC) and its downstream effector...
MAP kinase (MAPK). The normal physiological consequences of activating G\(_{\alpha}q\) in thyrocytes are proliferation, hormone synthesis and thyroglobulin (Tg) iodination (29, 36). However, the physiological or pathophysiological control of G\(_{\alpha}q/11\) signaling in thyrocytes or extrathyroidal TSHRs is not well-characterized despite multiple reports. For example, conditional deletion of G\(_{\alpha}q/11\) in mouse thyroid resulted in hypoplastic thyroid glands and severe hypothyroidism (34). It has also been shown that G\(_{\alpha}q/11\)-PKC dependent activation in TSHR transfected papillary cancer cells (line FTC236) resulted in the upregulation of a class of redox and metal ion scavengers which are cysteine-rich proteins known as metallothioneins (MTs) (37). Studies have also shown an indirect relationship of G\(_{\alpha}q/11\) activation to thyroid peroxidase formation (34, 38) and a congenital hypothyroidism phenotype (39).

Our docking studies with a modeled TMD (28) showed that the G\(_{\alpha}q/11\) activator molecule binds within the hydrophobic pocket of the TMD. By this analysis we saw that in addition to overlapping contacts with our agonist MS438 (G\(_{\alpha}q\) dominant), the MSq1 molecule also made contact with some unique resides helping to explain its selective allosteric G\(_{\alpha}q/11\) activation (Table 1). Furthermore, docking MSq1 to the TSH binding surface of the ECD resulted in docking scores that were more than 4 kcal/mol weaker than the top scores observed when docked to the TMD. Such differences represent ~786 times weaker binding indicating that this molecule, like our previously reported small molecules, is can be an allosteric molecule (17).

Despite tremendous progress into the molecular mechanism concerning contacts and activation of G proteins by GPCRs (40, 41) our understanding as to how structurally distinct ligands may lead to the stabilization of different “active states” of the receptors remains open. Homology modeling of the TSHR with the G\(_{q}\) heterodimer combined with mutational analysis of the transmembrane domain has indicated the principal determinants leading to the complex interaction (4, 14, 42) suggesting spatial conformation for selective G protein activation.

In this study, we observed that MSq1 is an activator of PLC (Figure 4A) and its downstream effectors—PKC and NFAT activation (Figure 4B). MSq1 showed increased phosphorylation of PKC. However, we failed to see any up regulation in the
mRNA levels of thyroid specific genes in contrast to the effect of TSH or our small molecule agonist MS438. On examining the proliferation of these cells, MSq1 alone did not induce any proliferation as seen with MS438 or TSH. It is generally accepted that the proliferation of thyroid cells by TSH is mediated in large part by the cAMP-PKA pathway (43, 44). In contrast, the MSq1 molecule showed the unique ability to suppress TSH induced proliferation. Since we did not observe any blockade of TSH induced cAMP by MSq1 (Figure S4) we hypothesized that suppression must be due to interference with the cAMP-PKA pathway and most likely by PKC activation. There exists cross-talk in downstream signaling of GPCRs (45) and it has been previously shown that PKC can suppress PKA induced activation (46) and functional interference between cAMP/PKA and PKC pathways is possible (47, 48). Thus, experiments carried out in the presence of a PKC inhibitor confirmed that inhibiting PKC in the presence of MSq1 and TSH showed a marked reduction in the suppressive effect of MSq1 on proliferation. Furthermore, pPKA levels showed a significant increase after exposure to the PKC inhibitor. The only study which supports a physiological role for the Goq/11 mediated signaling pathway in TSH induced hormone synthesis (34) was performed in Goq/11 knock out mice. However, the action of MSq1 on proliferation is opposite to the Goq/11 study. Our model would suggest that overt activation of the cAMP-PKA pathway by high concentrations of TSH leading to increased proliferation might be kept in check by the PLC-PKC pathway via Gq and thus maintain a balance in the endogenous proliferative capacity of thyrocytes differing with data that contradicts much of the literature which suggested that TSH stimulates differentiation and not proliferation of normal human thyrocytes (49).

In conclusion, we have identified a novel Goq/11 biased modulator of the TSHR with inhibitory effects on thyrocyte proliferation. The data illustrate the intertwining molecular mechanisms leading to this action. This raises the prospect of modulating biased TSHR signaling for more specific pharmacologic responses.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

AUTHOR CONTRIBUTIONS

RL responsible for design, execution of the experiments, data analysis, and manuscript writing. SM helped in the experiments
with western blots. RM helped in PCR experiments. BT helping in carrying out some faces experiments. MM did the modeling and in-silico docking studies. TD helped in data analysis and finalizing of the manuscript.

FUNDING
This work was supported in part by National Institute of Health (NIH) grant DK069713, the Segal Family Endowment, and the Veterans Administration Merit Award Program (to TD).

REFERENCES
1. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. (2005) 115:1972–83. doi:10.1172/JCI26031
2. Laugwitz KL, Allgeier A, Offermanns S, Spicher K, van Sande J, Dumont JE, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA. (1996) 93:116–20. doi:10.1073/pnas.93.1.116
3. Neumann S, Krause G, Claus M, Paschke R. Structural determinants for g protein activation and selectivity in the second intracellular loop of the thyrotropin receptor. Endocrinology. (2005) 146:477–85. doi:10.1210/en.2004-1045
4. Kleinau G, Jaeschke H, Worth CL, Mueller S, Gonzalez J, Paschke R, et al. Principles and determinants of G-protein coupling by the rhodopsin-like thyrotropin receptor. PLoS One. (2010) 5:e9745. doi:10.1371/journal.pone.0009745
5. Furmaniak J, Sanders J, Nunez Miguel R, Rees Smith B. Mechanisms of Action of TSHR Autoantibodies. Horm Metab Res. (2015) 47:735–52. doi:10.1055/s-0035-1595648
6. Sanders J, Chiragadze DY, Sanders P, Baker S, Sullivan A, Bhardwaja A, et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid. (2007) 17:395–410. doi:10.1089/thy.2007.0034
7. Sanders P, Young S, Sanders J, Kabelis K, Baker S, Sullivan A, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. (2011) 46:81–99. doi:10.1530/JME-10-0127
8. Schaarveldt J, Huth S, Meier R, Paschke R, Jaeschke H. Influence of the hinge region and its adjacent domains on binding and signaling patterns of the thyrotropin and follitropin receptor. PLoS One. (2014) 9:e111570. doi:10.1371/journal.pone.0111570
9. Schaarveldt J, Nagel MB, Huth S, Jaeschke H, Moretti R, Hintze V, et al. Rearrangement of the extracellular domain/Extracellular loop 1 interface is critical for thyrotropin receptor activation. J Biol Chem. (2016) 291:14095–108. doi:10.1074/jbc.M115.709659
10. Marckowski K, Kuchniak A, Mendieta S, Hoyer I, Witte F, Furtkert J, et al. Thyrotropin receptor: allosteric modulators illuminate intramolecular signaling mechanisms at the interface of ecto- and transmembrane domain. Mol Pharmacol. (2019) 96:452–62. doi:10.1124/mol.119.116947
11. Haas AK, Kleinau G, Hoyer I, Neumann S, Furtkert J, Rutz C, et al. Mutations that silence constitutive signaling activity in the allosteric ligand-binding site of the thyrotropin receptor. Cell Mol Life Sci. (2011) 68:159–67. doi:10.1007/s00018-010-0451-2
12. Wenzel-Seifert K, Seifert R. Molecular analysis of beta(2)-adrenoceptor coupling to G(s), G(i), and G(q)-proteins. Mol Pharmacol. (2000) 58:954–66. doi:10.1124/mol.58.5.954
13. Moller S, Vilo J, Croning MD. Prediction of the coupling specificity of G protein coupled receptors to their G proteins. Bioinformatics. (2001) 17(Suppl. 1):S174–81. doi:10.1093/bioinformatics/17.suppl_1.S174
14. Kleinau G, Haas AK, Neumann S, Worth CL, Hoyer I, Furkert J, et al. Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor. FASEB J. (2010) 24:2347–54. doi:10.1096/fj.09-149146
15. Neumann S, Padua U, Cullen MJ, Eliseeva E, Nir EA, Place RF, et al. An enantiomer of an oral small-molecule TSH receptor agonist exhibits improved pharmacologic properties. Front Endocrinol (Lausanne). (2016) 7:105. doi:10.3389/fendo.2016.00105
16. Neumann S, Gershengorn MC. Small molecule TSHR agonists and antagonists. Ann Endocrinol (Paris). (2011) 72:74–6. doi:10.1016/j.ando.2011.03.002
17. Latif R, Ali MR, Ma R, David M, Morshed SA, Ohlmeyer M, et al. A new small molecule antagonist selective for the thyrotropin receptor. Thyroid. (2015) 25:51–62. doi:10.1089/thy.2014.1119
18. Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, et al. A new small-molecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor. J Clin Endocrinol Metab. (2011) 96:548–54. doi:10.1210/jc.2010-1935
19. Marckowski K, Hoyer I, Specker E, Furtkert J, Rutz C, Neuenschwander M, et al. A newly highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of graves’ orbitopathy. Thyroid. (2019) 29:111–23. doi:10.1089/thy.2018.0349
20. Latif R, Realubit RB, Karan C, Mezei M, Davies TF. TSH receptor signaling abrogation by a novel small molecule. Front Endocrinol (Lausanne). (2016) 7:130. doi:10.3389/fendo.2016.00130
21. Luttrell LM, Maudsley S, Bohn LM. Fulfilling the promise of “Biased” G protein-coupled receptor agonism. Mol Pharmacol. (2015) 88:579–88. doi:10.1124/mol.115.099630
22. Ulooa-Aguirre A, Reiter E, Crepieux P. FSH receptor signaling: complexity of interactions and signal diversity. Endocrinology. (2018) 159:3020–35. doi:10.1210/en.2018-00452
23. White KL, Scopton AP, Rives ML, Bikbulatov RV, Polepally PR, Brown PJ, et al. Identification of novel functionally selective kappa-opioid receptor scaffolds. Mol Pharmacol. (2014) 85:83–90. doi:10.1124/mol.113.089649
24. Tschammer N, Bollinger S, Kenakin T, Gmeiner P. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol. (2011) 79:575–85. doi:10.1124/mol.110.068106
25. Morshed SA, Ma R, Latif R, Davies TF. How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis. J Autoimmun. (2013) 47:17–24. doi:10.1016/j.jaut.2013.07.009
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. (1976) 72:248–54. doi:10.1016/0003-2697(76)90527-3
27. Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. (2009) 150:519–29. doi:10.1210/en.2008-0878
28. Ali MR, Latif R, Davies TF, Mezei M. Monte Carlo loop refinement and virtual screening of the thyroid-stimulating hormone receptor transmembrane domain. J Biol Mol Struct Dyn. (2015) 33:1140–52. doi:10.1080/07391102.2014.932310
29. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev. (1992) 13:596–611. doi:10.1210/er.13.3.596

ACKNOWLEDGMENTS
We thank Dr. Bhasker Das from the Departments of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai for critical reading of our manuscript.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.00372/full#supplementary-material
30. Davey RA, MacLean HE. Current and future approaches using genetically modified mice in endocrine research. *Am J Physiol Endocrinol Metab.* (2006) 291:E429–38. doi: 10.1152/ajpendo.00124.2006

31. Neumann S, Huang W, Titus S, Krause G, Kleinau G, Alberobello AE, et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. *Proc Natl Acad Sci USA.* (2009) 106:12471–6. doi: 10.1073/pnas.0904056106

32. Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS, Gershengorn MC. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves’ orbital fibroblasts. *Thyroid.* (2012) 22:839–43. doi: 10.1089/thy.2011.0520

33. Laurent E, Mockel J, van Sande J, Graff I, Dumont JE. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. *Mol Cell Endocrinol.* (1987) 52:273–8. doi: 10.1016/0303-7207(87)90055-4

34. Kero J, Ahmed K, Wettschureck N, Tunaru S, Wintermantel T, Greiner E, et al. Thyrocyte-specific Gq/G_{11} deficiency impairs thyroid function and prevents goiter development. *J Clin Invest.* (2007) 117:2399–407. doi: 10.1172/JCI30380

35. Song Y, Massart C, Chico-Galdo V, Jin L, De Maertelaer V, Decoster C, et al. Species-specific thyroid signal transduction: conserved physiology, divergent mechanisms. *Mol Cell Endocrinol.* (2010) 319:56–62. doi: 10.1016/j.mce.2010.01.024

36. De Felice M, Postiglione MP, Di Lauro R. Minireview: thyrotropin receptor signaling in development and differentiation of the thyroid gland: insights from mouse models and human diseases. *Endocrinology.* (2004) 145:4062–7. doi: 12.1016/en.2004.0501

37. Back CM, Stohr S, Schafer EA, Bieberrmann H, Boekhoff I, Breit A, et al. Thyrotropin stimulates metallothionein 1 in thyrocytes via Gq/11- and PKC-dependent signaling. *J Mol Endocrinol.* (2013) 51:79–90. doi: 10.1530/JME-12-0200

38. Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, et al. Roles of hydrogen peroxide in thyroid physiology and disease. *J Clin Endocrinol Metab.* (2007) 92:5764–73. doi: 10.1210/jc.2007-0660

39. Garcia M, Gonzalez de Buitrago J, Jimenez-Roses M, Pardo L, Hinkle PM, Moreno JC. Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. *J Clin Endocrinol Metab.* (2017) 102:2433–42. doi: 10.1210/jc.2016-3977

40. Mahoney JP, Sunahara RK. Mechanistic insights into GPCR-G protein interactions. *Curr Opin Struct Biol.* (2016) 41:247–54. doi: 10.1016/j.sbi.2016.11.005

41. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature.* (2011) 477:549–55. doi: 10.1038/nature10361

42. Kleinau G, Neumann S, Gruters A, Krude H, Bieberrmann H. Novel insights on thyroid-stimulating hormone receptor signal transduction. *Endocr Rev.* (2013) 34:691–724. doi: 10.1210/er.2012-1072

43. Jin S, Hornicek FJ, Neylan D, Zakarija M, McKenzie JM. Evidence that adenosine 3’,5’-monophosphate mediates stimulation of thyroid growth in FRTL5 cells. *Endocrinology.* (1986) 119:802–10. doi: 10.1210/endo-119-2-802

44. Tramontano D, Moses AC, Veneziani RM, Ingbar SH. Adenosine 3’5’-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells. *Endocrinology.* (1988) 122:127–32. doi: 10.1210/endo-122-1-127

45. Hur EM, Kim KT. G protein-coupled receptor signaling and cross-talk: achieving rapidity and specificity. *Cell Signal.* (2002) 14:397–405. doi: 10.1016/S0898-6568(01)00258-3

46. Lesage GD, Marucci L, Alvaro D, Glaser SS, Benedetti A, Marziani M, et al. Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. *Hepatology.* (2002) 36:641–51. doi: 10.1053/hlpe.2002.35537

47. Laglia G, Zeiger MA, Leipricht A, Caturegli P, Levine MA, Kohn LD, et al. Increased cyclic adenosine 3’5’-monophosphate inhibits G protein-coupled activation of phospholipase C in rat FRTL-5 thyroid cells. *Endocrinology.* (1996) 137:3170–6. doi: 10.1210/endo-137-8.8754735

48. Sho KM, Okajima F, Abdul Majid M, Kondo Y. Reciprocal modulation of thyrotropin actions by P1-purinergic agonists in FRTL-5 thyroid cells. *Endocrinology.* (1996) 137:3170–6. doi: 10.1210/endo.137.8.8754735

49. Morgan SJ, Neumann S, Marcus-Samuels B, Gershengorn MC. Thyrotropin stimulates differentiation not proliferation of normal human thyrocytes in culture. *Front Endocrinol (Lausanne).* (2016) 7:168. doi: 10.3389/fendo.2016.00168

Conflict of Interest: TD is a member of the Board of Kronus Inc, Idaho.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Latif, Morshed, Ma, Tokat, Mezei and Davies. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.